Alizapride


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Nausea and vomiting 75-300 mg/day in divided doses. IV/IM Nausea and vomiting associated with cancer chemotherapy 2-5 mg/kg/day in 2 divided doses (1st dose 30 mins before and 2nd dose 4-8 hr after administration of chemotherapy). Max: 4.5 g/course of chemotherapy.
Dosage Details
Oral
Nausea and vomiting
Adult: 75-300 mg/day in divided doses.
Child: 5 mg/kg/day.

Parenteral
Nausea and vomiting associated with cancer chemotherapy
Adult: 2-5 mg/kg/day given by IV/IM in 2 divided doses. 1st dose to be administered 30 min before and the next dose 4-8 hr after admin of cytotoxic drug. For highly emetogenic regimens requiring doses >5 mg/kg, dose may be given via IV infusion over 15 min every 2 hr for 5 doses. Start infusion 30 min before admin of cytotoxic drug. Max: 4.5 g/course of chemotherapy.
Contraindications
Pheochromocytoma, Parkinson's disease, conditions where activation of GI motility is contraindicated (e.g. GI perforation or sub-occlusion).
Special Precautions
Caution in renal impairment. May impair ability to drive or operate machinery.
Adverse Reactions
Drowsiness, dizziness, headache, diarrhoea, extrapyramidal symptoms, amenorrhoea, galactorrhoea.
Food Interaction
Avoid alcohol.
Action
Description: Alizapride is a methoxybenzamide that is structurally related to metoclopramide. It is a dopamine antagonist with and antiemetic property.
Pharmacokinetics:
Absorption: Well absorbed after oral admin.
Excretion: Excreted mainly unchanged in urine. Elimination half-life: about 3 hr.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Alizapride from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in